

Satoshi Morita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4475828/publications.pdf>

Version: 2024-02-01

166
papers

12,012
citations

201385

27
h-index

26548

107
g-index

170
all docs

170
docs citations

170
times ranked

10896
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 72-82.	5.2	62
2	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	2.7	9
3	Differences between subjective and objective sleep duration according to actual sleep duration and sleep-disordered breathing: the Nagahama Study. <i>Journal of Clinical Sleep Medicine</i> , 2022, 18, 851-859.	1.4	7
4	Exploratory analysis of baseline tumor burden in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 87-87.	0.8	1
5	Clinical results of dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring for liver tumors using a gimbal-mounted linac: A multi-institutional phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 441-441.	0.8	1
6	Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an <i>ad hoc</i> analysis of the JBCRG-C06 Safari study. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 545-553.	0.6	4
7	A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1345-1356.	0.8	3
8	Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201). <i>BMC Cancer</i> , 2022, 22, 170.	1.1	5
9	Evaluation of respiratory rate monitoring performance using a home oxygen monitoring device among patients with interstitial lung disease and chronic obstructive pulmonary disease.. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2022, 39, e2022007.	0.2	0
10	Randomized controlled trial of the significance of combined use with Ninjinâ€™yoeito in CapeOX + Bmab therapy for patients with unresectable advanced/recurrent colorectal cancer. <i>Medicine, Case Reports and Study Protocols</i> , 2022, 3, e0196.	0.0	0
11	Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9117-9117.	0.8	0
12	A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced nonâ€™small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9097-9097.	0.8	1
13	A semiparametric Bayesian approach to population finding with timeâ€™toâ€™event and toxicity data in a randomized clinical trial. <i>Biometrics</i> , 2021, 77, 634-648.	0.8	1
14	Are volume-dependent parameters in positron emission tomography predictive of postoperative recurrence after resection in patients with thymic carcinoma?. <i>Surgery Today</i> , 2021, 51, 322-326.	0.7	3
15	Employing multiple-attribute utility technology to evaluate publicity activities for cancer information and counseling programs in Japan. <i>Journal of Cancer Policy</i> , 2021, 27, 100261.	0.6	0
16	Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure. <i>Heart</i> , 2021, 107, 705-712.	1.2	16
17	Impact of sleep-disordered breathing on glucose metabolism among individuals with a family history of diabetes: the Nagahama study. <i>Journal of Clinical Sleep Medicine</i> , 2021, 17, 129-140.	1.4	1
18	Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatinâ€™based or irinotecanâ€™based therapy for colorectal cancer. <i>Cancer Science</i> , 2021, 112, 1567-1578.	1.7	5

#	ARTICLE	IF	CITATIONS
19	Estimating Similarity of Dose-Response Relationships in Phase I Clinical Trials Case Study in Bridging Data Package. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1639.	1.2	3
20	Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). <i>Oncologist</i> , 2021, 26, e954-e962.	1.9	14
21	Proposal of a novel H category-based classification of colorectal liver metastases based on a Japanese nationwide survey. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 317-326.	1.4	10
22	Multiparametric magnetic resonance imaging facilitates the selection of patients prior to fertility-sparing management of endometrial cancer. <i>Abdominal Radiology</i> , 2021, 46, 4410-4419.	1.0	4
23	Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). <i>International Journal of Clinical Oncology</i> , 2021, 26, 1229-1236.	1.0	3
24	Markers of cardiovascular disease risk in sleep-disordered breathing with or without comorbidities: the Nagahama Study. <i>Journal of Clinical Sleep Medicine</i> , 2021, 17, 2467-2475.	1.4	1
25	The 2020 Edition of the Clinical Guidelines for Lung Cancer: Challenges and Future Perspectives. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 163-170.	0.0	0
26	Lymph node dissection in thymic carcinomas and neuroendocrine carcinomas. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 33, 242-249.	0.5	3
27	Impact of <i>UGT1A1</i> genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 4669-4678.	1.7	8
28	Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. <i>European Journal of Cancer</i> , 2021, 154, 296-306.	1.3	5
29	Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1523-1532.	0.5	57
30	Effects of Goshajinkigan (TJ-107) for oxaliplatin-induced peripheral neurotoxicity using the functional assessment of cancer therapy/gynecologic oncology group 12-item neurotoxicity questionnaire in a Phase II, multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1473.	0.3	2
31	Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2020, 30, 450-457.	0.9	3
32	A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. <i>Investigational New Drugs</i> , 2020, 38, 445-456.	1.2	16
33	Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 160-167.	2.7	3
34	A Randomized Controlled Trial of Telemedicine for Long-Term Sleep Apnea Continuous Positive Airway Pressure Management. <i>Annals of the American Thoracic Society</i> , 2020, 17, 329-337.	1.5	31
35	An adaptive power prior for sequential clinical trials Application to bridging studies. <i>Statistical Methods in Medical Research</i> , 2020, 29, 2282-2294.	0.7	25
36	Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. <i>Breast Cancer</i> , 2020, 27, 389-398.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Prolonged air leak after reoperative pulmonary resection (with prior ipsilateral chest surgery). <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 31, 544-546.	0.5	1
38	Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. <i>Cancer Medicine</i> , 2020, 9, 9419-9430.	1.3	5
39	Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsies. <i>Surgical Oncology</i> , 2020, 35, 447-452.	0.8	2
40	Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. <i>Cancer Medicine</i> , 2020, 9, 9246-9255.	1.3	2
41	Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trial. <i>European Journal of Cancer</i> , 2020, 132, 159-167.	1.3	2
42	Intake frequency of vegetables or seafoods negatively correlates with disease activity of rheumatoid arthritis. <i>PLoS ONE</i> , 2020, 15, e0228852.	1.1	7
43	Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRC-cohort study 01. <i>Breast Cancer</i> , 2020, 27, 631-641.	1.3	6
44	Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 1908-1917.	0.7	7
45	Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. <i>Cancer Medicine</i> , 2020, 9, 1779-1789.	1.3	6
46	Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 608-615.	2.2	10
47	Predictive factors for structural remission using abatacept: Results from the ABROAD study. <i>Modern Rheumatology</i> , 2019, 29, 406-412.	0.9	7
48	Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 589-595.	0.9	96
49	Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1367-1376.	1.0	4
50	Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring. <i>Clinical Trials</i> , 2019, 16, 512-522.	0.7	13
51	Risk-benefit point of the Model for End-stage Liver Disease score in patients waiting for deceased-donor liver transplantation: A single-center experience. <i>Hepatology Research</i> , 2019, 49, 687-694.	1.8	3
52	Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. <i>Breast</i> , 2019, 47, 1-9.	0.9	13
53	A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208). <i>Annals of Surgery</i> , 2019, 270, 230-237.	2.1	41
54	A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 867-874.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients. <i>BMJ Open</i> , 2019, 9, e033131.	0.8	32
56	Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. <i>Journal of Cancer</i> , 2019, 10, 5130-5138.	1.2	1
57	Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. <i>Breast Cancer</i> , 2019, 26, 282-289.	1.3	17
58	Bayesian analysis of longitudinal dyadic data with informative missing data using a dyadic shared-parameter model. <i>Statistical Methods in Medical Research</i> , 2019, 28, 70-83.	0.7	2
59	EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs). <i>Journal of Clinical Oncology</i> , 2019, 37, 652-652.	0.8	2
60	Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2. <i>Journal of Clinical Oncology</i> , 2019, 37, 8-8.	0.8	3
61	Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapelRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 711-711.	0.8	0
62	A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial. <i>Gastric Cancer</i> , 2018, 21, 811-818.	2.7	11
63	Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 981-989.	1.1	29
64	Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. <i>Lung Cancer</i> , 2018, 117, 14-19.	0.9	63
65	Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trial. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 870-883.	0.4	0
66	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 312 To colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 660-671.	5.1	107
67	Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study. <i>Breast Cancer</i> , 2018, 25, 108-117.	1.3	4
68	Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e153-e161.	1.0	7
69	Factors associated with prolonged time to treatment failure with fulvestrant 500mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study. <i>Current Medical Research and Opinion</i> , 2018, 34, 49-54.	0.9	8
70	Comprehensive data of 3,820 patients newly diagnosed with colorectal liver metastasis between 2005 and 2007: report of a nationwide survey in Japan. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2018, 25, 115-123.	1.4	17
71	Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 1000-1006.	0.8	55
72	A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial. <i>Cancer Medicine</i> , 2018, 7, 4217-4227.	1.3	12

#	ARTICLE	IF	CITATIONS
73	Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341878624.	0.6	2
74	A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): therapeutic efficacy and clinical implications of circulating endothelial cells. <i>Cancer Medicine</i> , 2018, 7, 2442-2451.	1.3	10
75	The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C). <i>Journal of Cancer</i> , 2018, 9, 1725-1730.	1.2	17
76	A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). <i>European Journal of Cancer</i> , 2018, 101, 220-228.	1.3	11
77	Non-obese visceral adiposity is associated with the risk of atherosclerosis in Japanese patients with rheumatoid arthritis: a cross-sectional study. <i>Rheumatology International</i> , 2018, 38, 1679-1689.	1.5	12
78	Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. <i>International Journal of Clinical Oncology</i> , 2018, 23, 980-988.	1.0	15
79	ç”Ÿç%©çµ±è~ã ã@ãŸçŽ. <i>Japanese Journal of Lung Cancer</i> , 2018, 58, 891-893.	0.0	0
80	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. <i>Breast Cancer</i> , 2017, 24, 111-120.	1.3	21
81	A simulation study of methods for selecting subgroup-specific doses in phase 1 trials. <i>Pharmaceutical Statistics</i> , 2017, 16, 143-156.	0.7	10
82	Bayesian Population Finding with Biomarkers in a Randomized Clinical Trial. <i>Biometrics</i> , 2017, 73, 1355-1365.	0.8	16
83	Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies. <i>Rheumatology</i> , 2017, 56, 1217-1226.	0.9	27
84	Breathing-swallowing discoordination is associated with frequent exacerbations of COPD. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000202.	1.2	38
85	S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. <i>ESMO Open</i> , 2017, 2, e000135.	2.0	17
86	Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study. <i>Medical Oncology</i> , 2017, 34, 134.	1.2	16
87	Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 100-103.	1.1	9
88	Predictability of survival outcome by early tumor shrinkage (ETS) at 8 weeks with cutoff value of 20% in metastatic colorectal cancer (mCRC) patients treated with mFOLFOX6 plus bevacizumab (bev) or FOLFIRI plus bev as first-line chemotherapy (1st-CTx): Validation in the phase III WJOG4407G trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 729-729.	0.8	1
89	Meta-analysis of Patient-level Data on Therapeutic Effects of TJ-14 (Hangeshashinto) for Gastroenterological Cancer Chemotherapy-induced Severe Oral Mucositis with the HANGESHA-G and HANGESHA-Cs : protocol paper. <i>Annals of Cancer Research and Therapy</i> , 2017, 25, 92-94.	0.1	0
90	MEDICAL STATISTICS FOR SURGEONS. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical)</i> Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.0	0

#	ARTICLE	IF	CITATIONS
91	Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016, 35, 102.	4.9	12
92	Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naïve Rheumatoid Arthritis: Results from the ABROAD Study. <i>Journal of Rheumatology</i> , 2016, 43, 1974-1983.	1.0	23
93	Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). <i>European Journal of Cancer</i> , 2016, 65, 164-171.	1.3	40
94	A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood stem-cell transplantation. <i>Molecular and Clinical Oncology</i> , 2016, 4, 965-970.	0.4	0
95	Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial. <i>Pharmaceutical Statistics</i> , 2016, 15, 420-429.	0.7	9
96	Diagnostic criteria that can most accurately differentiate allergic bronchopulmonary mycosis from other eosinophilic lung diseases: A retrospective, single-center study. <i>Respiratory Investigation</i> , 2016, 54, 264-271.	0.9	12
97	A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey. <i>International Journal of Hematology</i> , 2016, 103, 322-333.	0.7	13
98	Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. <i>International Journal of Clinical Oncology</i> , 2016, 21, 118-125.	1.0	28
99	Prognostic factors in patients with advanced thymic carcinoma treated with chemotherapy: A retrospective analysis of 289 patients from NEJ023 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 8567-8567.	0.8	1
100	Impact of <i>UGT1A1</i> genotype on overall survival in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens. <i>Journal of Clinical Oncology</i> , 2016, 34, 3571-3571.	0.8	0
101	Phase II study on radiofrequency ablation in early breast cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, e12536-e12536.	0.8	0
102	Reply. <i>Annals of Thoracic Surgery</i> , 2015, 100, 1968-1969.	0.7	0
103	Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 626.	1.1	13
104	Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	24
105	Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. <i>International Journal of Clinical Oncology</i> , 2015, 20, 709-722.	1.0	7
106	A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). <i>Lung Cancer</i> , 2015, 87, 136-140.	0.9	16
107	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 824-832.	2.7	91
108	Video-Assisted Thoracoscopic Lobectomy Versus Stereotactic Radiotherapy for Stage I Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2015, 99, 1122-1129.	0.7	87

#	ARTICLE	IF	CITATIONS
109	Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. <i>European Journal of Cancer</i> , 2015, 51, 808-816.	1.3	40
110	Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation. <i>Lung Cancer</i> , 2015, 88, 181-186.	0.9	29
111	Incorporating Historical Data in Bayesian Phase I Trial Design: The Caucasian-to-Asian Toxicity Tolerability Problem. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 93-99.	0.8	6
112	The utility of bi-weekly eribulin therapy for metastatic breast cancer: A Japanese multicenter phase II study (JUST-STUDY).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1026-1026.	0.8	1
113	Impact of <i>UGT1A1</i> genotype on prognosis in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3525-3525.	0.8	1
114	A randomized phase II trial of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment versus SP randomized PII trial (XParTS II).. <i>Journal of Clinical Oncology</i> , 2015, 33, 105-105.	0.8	5
115	The impact of early tumor shrinkage on survival in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 679-679.	0.8	2
116	A randomized 2X2 phase II trial comparing two and four courses of S-1/cisplatin (SC) and paclitaxel/cisplatin (PC) as neoadjuvant chemotherapy for locally resectable advanced gastric cancer: Survival results of COMPASS.. <i>Journal of Clinical Oncology</i> , 2015, 33, 111-111.	0.8	0
117	Subset analysis of COMPASS: A randomized 2X2 phase II trial comparing two and four courses of S-1/cisplatin (SC) and paclitaxel/cisplatin (PC) as neoadjuvant chemotherapy for locally advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15067-e15067.	0.8	0
118	Exploring Ethnic Differences in Toxicity in Early-Phase Clinical Trials for Oncology Drugs. <i>Therapeutic Innovation and Regulatory Science</i> , 2014, 48, 644-650.	0.8	4
119	A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study). <i>Oncologist</i> , 2014, 19, 1131-1132.	1.9	15
120	Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation. <i>Statistics in Medicine</i> , 2014, 33, 4008-4016.	0.8	12
121	Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis. <i>European Journal of Cancer</i> , 2014, 50, 2932-2938.	1.3	93
122	CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. <i>European Journal of Radiology</i> , 2014, 83, 32-38.	1.2	65
123	Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3586-3586.	0.8	2
124	Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3655-TPS3655.	0.8	1
125	NEJ009 trial: A randomized phase III study of gefitinib (G) in combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8131-TPS8131.	0.8	6
126	Harvesting lymph nodes in gastric cancer surgery: A prospective randomized controlled study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 28-28.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Potential predictive markers of chemotherapy for advanced gastric cancer: Biomarker study in GC0301/TOP-002, randomized phase III study of irinotecan plus S-1 versus S-1.. Journal of Clinical Oncology, 2014, 32, 55-55.	0.8	0
128	Subgroup analyses of randomized phase II study on gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, e20618-e20618.	0.8	0
129	An internally and externally validated nomogram to predict severe neutropenia in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens.. Journal of Clinical Oncology, 2014, 32, 3543-3543.	0.8	0
130	First-line gemcitabine versus treatment of physician's choice in patients with metastatic and stage IV breast cancer: A prospective cohort study.. Journal of Clinical Oncology, 2014, 32, e12013-e12013.	0.8	0
131	The Pathological Response to Anthracycline is Associated with Topoisomerase III \pm Gene Amplification in the HER2 Breast Cancer Subset. Journal of Surgery and Science, 2014, 2, 10-12.	0.0	1
132	Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. Anticancer Research, 2014, 34, 3583-8.	0.5	2
133	Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial. Journal of Clinical Oncology, 2013, 31, 4438-4444.	0.8	439
134	Double-Blind, Placebo-Controlled, Randomized Phase II Study of TJ-14 (Hangeshashinto) for Infusional Fluorinated-Pyrimidine-based Colorectal Cancer Chemotherapy-induced Oral Mucositis. Annals of Cancer Research and Therapy, 2013, 21, 26-30.	0.1	1
135	Prospective analysis of UGT1A1 genotyping for predicting toxicities in advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens: Interim safety analysis of a Japanese observational study.. Journal of Clinical Oncology, 2013, 31, 3535-3535.	0.8	1
136	A comparison of postoperative quality of life after open and laparoscopic gastrectomy for early gastric cancer: A multicenter, nonrandomized, controlled study (CCOG 0802).. Journal of Clinical Oncology, 2013, 31, 4088-4088.	0.8	1
137	Multicenter, phase II study of trastuzumab and paclitaxel to treat HER2-positive, metastatic gastric cancer patients naive to trastuzumab (JFMC45-1102).. Journal of Clinical Oncology, 2013, 31, 4096-4096.	0.8	3
138	Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01).. Journal of Clinical Oncology, 2013, 31, 613-613.	0.8	1
139	SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, LBA4002-LBA4002.	0.8	1
140	Efficacy and safety of trastuzumab (T-mab) and paclitaxel for T-mab naïve patients with HER2 positive previously treated metastatic gastric cancer (JFMC45-1102).. Journal of Clinical Oncology, 2013, 31, 63-63.	0.8	2
141	Randomized phase II study of mixing steroid to reduce venous pain in patients with colorectal cancer receiving oxaliplatin through peripheral vein (APOLLO study).. Journal of Clinical Oncology, 2013, 31, 474-474.	0.8	0
142	A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Group (KBOG) 1101 study.. Journal of Clinical Oncology, 2013, 31, 1047-1047.	0.8	1
143	SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, LBA4002-LBA4002.	0.8	1
144	Dynamic treatment regimen analysis to determine which treatment sequence can prolong survival of NSCLC patients.. Journal of Clinical Oncology, 2013, 31, e19010-e19010.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel + cyclophosphamide + capecitabine followed by 5-fluorouracil + epirubicin + cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study).. Journal of Clinical Oncology, 2013, 31, 1048-1048.	0.8	0
146	Evaluation of UGT1A1 genotyping for predicting individual toxicity of irinotecan plus platinum analog regimens: Interim safety analysis of a prospective observational study.. Journal of Clinical Oncology, 2013, 31, 11049-11049.	0.8	0
147	A prospective cohort study to reduce operative risk in stage I gastric cancer patients with metabolic syndrome: Preoperative exercise versus surgery alone.. Journal of Clinical Oncology, 2013, 31, e15112-e15112.	0.8	0
148	Early results of a randomized phase II, compass trial to compare regimen and duration of neoadjuvant chemotherapy for gastric cancer.. Journal of Clinical Oncology, 2013, 31, 4102-4102.	0.8	0
149	Prior Effective Sample Size in Conditionally Independent Hierarchical Models. Bayesian Analysis, 2012, 7, .	1.6	30
150	A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). BMC Cancer, 2012, 12, 307.	1.1	12
151	Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. Gastric Cancer, 2012, 15, 245-251.	2.7	19
152	Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial.. Journal of Clinical Oncology, 2012, 30, 4002-4002.	0.8	17
153	Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).. Journal of Clinical Oncology, 2012, 30, 7521-7521.	0.8	71
154	A multidisciplinary treatment comprising standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for Ewing sarcoma family of tumor (ESFT) in Japan: Results of the first Japan Ewing Sarcoma Study (JESS) 04.. Journal of Clinical Oncology, 2012, 30, 9574-9574.	0.8	0
155	What factors affect long-term survival after responding to gefitinib in advanced non-small cell lung cancer? Real-world evidence.. Journal of Clinical Oncology, 2012, 30, e18007-e18007.	0.8	0
156	Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West. Statistics in Medicine, 2011, 30, 2090-2097.	0.8	18
157	Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics. Statistics in Biosciences, 2010, 2, 1-17.	0.6	29
158	A Bayesian Hierarchical Mixture Model for Platelet-Derived Growth Factor Receptor Phosphorylation to Improve Estimation of Progression-Free Survival in Prostate Cancer. Journal of the Royal Statistical Society Series C: Applied Statistics, 2010, 59, 19-34.	0.5	6
159	A Human Epidermal Growth Factor Receptor 2 Expression-based Approach to Neoadjuvant Chemotherapy for Operable Breast Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 620-626.	0.6	4
160	Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. Journal of Clinical Oncology, 2010, 28, 5240-5246.	0.8	161
161	Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. New England Journal of Medicine, 2010, 362, 2380-2388.	13.9	5,032
162	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 121-128.	5.1	3,794

#	ARTICLE	IF	CITATIONS
163	Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS) Tj ETQq1 1 0.784314 rg55/Overl	0.6	1
164	A Decision Analysis of Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia In First Remission Who Lack An HLA-Matched Sibling. Blood, 2010, 116, 3527-3527.	3.2	182
165	Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-EGFR Mutations. Clinical Cancer Research, 2009, 15, 4493-4498.	0.8	188
166	Determining the Effective Sample Size of a Parametric Prior. Biometrics, 2008, 64, 595-602.		